Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Bone: in search of the perfect SERM--a 5-year study of bazedoxifene.

× No keyword cloud information.

10 in total

1. Safety and tolerability of bazedoxifene in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled phase 3 trial.

Authors: T J de Villiers; A A Chines; S Palacios; P Lips; A Z Sawicki; A B Levine; C Codreanu; N Kelepouris; J P Brown
Journal: Osteoporos Int Date: 2010-06-10 Impact factor: 4.507

2. Lasofoxifene in postmenopausal women with osteoporosis.

Authors: Steven R Cummings; Kristine Ensrud; Pierre D Delmas; Andrea Z LaCroix; Slobodan Vukicevic; David M Reid; Steven Goldstein; Usha Sriram; Andy Lee; John Thompson; Roisin A Armstrong; David D Thompson; Trevor Powles; Jose Zanchetta; David Kendler; Patrick Neven; Richard Eastell
Journal: N Engl J Med Date: 2010-02-25 Impact factor: 91.245

3. Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipid levels in early postmenopausal women: three-year data from 2 double-blind, randomized, placebo-controlled trials.

Authors: C C Johnston; N H Bjarnason; F J Cohen; A Shah; R Lindsay; B H Mitlak; W Huster; M W Draper; K D Harper; H Heath; C Gennari; C Christiansen; C D Arnaud; P D Delmas
Journal: Arch Intern Med Date: 2000 Dec 11-25

4. Sustained efficacy and safety of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled study.

Authors: S L Silverman; A A Chines; D L Kendler; A W C Kung; C S Teglbjærg; D Felsenberg; N Mairon; G D Constantine; J D Adachi
Journal: Osteoporos Int Date: 2011-07-21 Impact factor: 4.507

5. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators.

Authors: B Ettinger; D M Black; B H Mitlak; R K Knickerbocker; T Nickelsen; H K Genant; C Christiansen; P D Delmas; J R Zanchetta; J Stakkestad; C C Glüer; K Krueger; F J Cohen; S Eckert; K E Ensrud; L V Avioli; P Lips; S R Cummings
Journal: JAMA Date: 1999-08-18 Impact factor: 56.272

6. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene.

Authors: Silvana Martino; Jane A Cauley; Elizabeth Barrett-Connor; Trevor J Powles; John Mershon; Damon Disch; Roberta J Secrest; Steven R Cummings
Journal: J Natl Cancer Inst Date: 2004-12-01 Impact factor: 13.506

7. Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial.

Authors: Stuart L Silverman; Claus Christiansen; Harry K Genant; Slobodan Vukicevic; José R Zanchetta; Tobie J de Villiers; Ginger D Constantine; Arkadi A Chines
Journal: J Bone Miner Res Date: 2008-12 Impact factor: 6.741

8. Efficacy of tissue-selective estrogen complex of bazedoxifene/conjugated estrogens for osteoporosis prevention in at-risk postmenopausal women.

Authors: Robert Lindsay; J Christopher Gallagher; Risa Kagan; James H Pickar; Ginger Constantine
Journal: Fertil Steril Date: 2009-07-26 Impact factor: 7.329

9. Evaluation of bazedoxifene/conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic parameters and overall safety profile.

Authors: Rogerio A Lobo; Joann V Pinkerton; Margery L S Gass; Maxine H Dorin; Sheila Ronkin; James H Pickar; Ginger Constantine
Journal: Fertil Steril Date: 2009-07-26 Impact factor: 7.329

10. Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX.

Authors: John A Kanis; Helena Johansson; Anders Oden; Eugene V McCloskey
Journal: Bone Date: 2009-02-28 Impact factor: 4.398

10 in total